VivoSeq
Other

Transplantation

2

Pipeline Programs↗

41

Active Trials↗

14

Companies Involved↗

Transplantation is an early-stage landscape with 2 programs across 14 companies. The most active players are Astellas, Veloxis Pharmaceuticals, Sumitomo Pharma Switzerland GmbH.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

25/100

Mech. Concentration

100/100

Completion Rate

74/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

1 program

Phase 2V

Veloxis Pharmaceuticals

1 program

Phase 2S

Sumitomo Pharma Switzerland GmbH

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalA

Acrotech Biopharma Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Tacrolimus

Veloxis Pharmaceuticals

Tacrolimus Prolonged Release

Astellas

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

224

clinical trials

Completed99 · 44%
Unknown status47 · 21%
Terminated27 · 12%
Recruiting25 · 11%
Not yet recruiting9 · 4%
Withdrawn7 · 3%
Other10 · 4%

Clinical Trials

Trial Activity

224 trials

Fecal Transplantation to Eradicate Colonizing Emergent Superbugs
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05035342·214 enrolled
Human Upper Extremity Allotransplantation
Recruiting·JJohns Hopkins University·Phase 2·NCT01459107·30 enrolled
Human Craniomaxillofacial Allotransplantation
Recruiting·JJohns Hopkins University·Phase 2·NCT01889381·15 enrolled
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Recruiting·CCenter for International Blood and Marrow Transplant Research·Phase 3·NCT00785525·60,000 enrolled
Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
Recruiting·—·Phase 2·NCT04627753·30 enrolled
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Recruiting·IIstituto Clinico Humanitas·Phase 2·NCT06892223·42 enrolled
Human Penile Allotransplantation
Recruiting·JJohns Hopkins University·Phase 2/3·NCT02395497·60 enrolled
Emdogain Adjunctive to Autotransplantation
Recruiting·UUniversidad Complutense de Madrid·Phase 4·NCT06250088·20 enrolled
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
Recruiting·NNew York Blood Center·Phase 2·NCT01656603·9,999 enrolled
Advancing Transplantation Outcomes in Children
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06055608·200 enrolled
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification
Recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT06612944·40 enrolled
Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction
Recruiting·NNantes University Hospital·Phase 3·NCT05562869·30 enrolled
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Recruiting·—·Phase 3·NCT05477589·170 enrolled
Custodiol-N Solution Compared With Custodiol Solution in Organ Transplantation (Kidney, Liver and Pancreas)
Recruiting·DDr. F. Köhler Chemie GmbH·Phase 3·NCT03627013·362 enrolled
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
Recruiting·NNantes University Hospital·Phase 2·NCT06252870·82 enrolled
Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)